Outlook Therapeutics Inc OTLK:NASDAQ

Last Price$1.63NASDAQ Previous Close - Last Trade as of 4:00PM ET 5/17/22

Today's Change+0.03(1.87%)
Bid (Size)$1.62 (16)
Ask (Size)$1.63 (19)
Day Low / High$1.56 - 1.64
Volume479.9 K
 

View Biotechnology IndustryPeer Comparison as of 05/17/2022

 

Outlook Therapeutics Inc ( NASDAQ )

Price: $1.63
Change: +0.03 (1.87%)
Volume: 479.9 K
4:00PM ET 5/17/2022
 
 

Heron Therapeutics Inc ( NASDAQ )

Price: $3.79
Change: +0.25 (7.06%)
Volume: 2.2 M
4:00PM ET 5/17/2022
 
 

Kezar Life Sciences Inc ( NASDAQ )

Price: $6.63
Change: +0.61 (10.13%)
Volume: 1.3 M
4:00PM ET 5/17/2022
 
 

ADMA Biologics Inc ( NASDAQ )

Price: $2.02
Change: +0.15 (8.02%)
Volume: 3.2 M
4:00PM ET 5/17/2022
 
 

Rigel Pharmaceuticals Inc ( NASDAQ )

Price: $2.21
Change: +0.16 (7.80%)
Volume: 1.7 M
4:00PM ET 5/17/2022
 

Read more news Recent News

Outlook Therapeutics Submits Biologics License Application for Wet Age-Related Macular Degeneration Treatment
10:14AM ET 3/31/2022 MT Newswires

Outlook Therapeutics (OTLK) said Thursday it submitted a biologics license application to the Food and Drug Administration for its ONS-5010 investigational...

Insider Buy: Outlook Therapeutics
5:45PM ET 2/23/2022 MT Newswires

Kurt J Hilzinger, Director, on February 22, 2022, executed a purchase for 175,132 shares in Outlook Therapeutics (OTLK) for $256,970. Following the Form 4...

--Ascendiant Capital Adjusts Price Target on Outlook Therapeutics to $7.25 From $7, Maintains Buy Rating
10:26AM ET 12/27/2021 MT Newswires

(MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may...

Insider Buy: Outlook Therapeutics
6:18AM ET 12/02/2021 MT Newswires

Ghiath M. Sukhtian, 10% Owner, Director, on November 29, 2021, executed a purchase for 16,000,000 shares in Outlook Therapeutics (OTLK) for $20,000,000....

View all Commentary and Analysis

Outlook Therapeutics (OTLK) Investor Presentation - Slideshow
4:48PM ET 5/13/2022 Seeking Alpha

Outlook Therapeutics: Likely FDA Approval, Possible Buyout
2:00PM ET 1/21/2022 Seeking Alpha

Wall Street Breakfast: The Week Ahead (Podcast)
7:21AM ET 10/10/2021 Seeking Alpha

Wall Street Breakfast: The Week Ahead
7:03AM ET 10/10/2021 Seeking Alpha

Company Profile

Business DescriptionOutlook Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of ONS-5010/LYTENAVA. Its pipeline includes unmet patient needs, repackaged IV bevacizumab, and anti-VEGF. The company was founded by Pankaj Mohan on January 5, 2010 and is headquartered in Iselin, NJ. View company web site for more details
Address485 Route 1 South
Iselin, New Jersey 08830
Phone+1.609.619.3990
Number of Employees56
Recent SEC Filing05/13/202210-Q
President, Chief Executive Officer & DirectorC. Russell Trenary
Chief Operating OfficerTerry Dagnon
CFO, Secretary, Treasurer & DirectorLawrence A. Kenyon
Senior Vice President-Clinical DevelopmentJennifer M. Kissner

Company Highlights

Price Open$1.61
Previous Close$1.60
52 Week Range$1.19 - 3.27
Market Capitalization$368.3 M
Shares Outstanding225.9 M
SectorHealth Technology
IndustryBiotechnology
Next Earnings Announcement08/12/2022

Options Summary

Call Open Interest (1d)*
Put Open Interest (1d)*
Call Volume (1d)*
Put Volume (1d)*
Put Call Open Interest Ratio (1d)*
Put Call Volume Ratio (1d)*
* Data delayed by up to 15 minutes

View all fundamentalsFundamentals

Price / EarningsN/A
Earnings per Share-$0.31
Beta vs. S&P 500N/A
Revenue$3.1 M
Net Profit MarginN/A
Return on Equity-244.94%

Analyst Ratings as of 02/14/2022

Buy
3
Overweight
0
Hold
0
Underweight
0
Sell
0
Consensus RecommendationConsensus Icon
Powered by Factset